类风湿性关节炎和间质性肺病患者肺和关节介入的相关性：横断面研究

1。加布里埃尔SE。类风湿性关节炎的流行病学。Rheum Dis Clin North Am。2001; 27：269-81。

2。Tanoue LT。类风湿性关节炎的肺部表现。Clin Chest Med。1998; 19：667-85，viii。

3。Olson AL，Swigris JJ，Sprunger DB，et al。类风湿性关节炎 - 间质性肺病相关死亡率。Am J Respir Crit Care Med。2011; 183：372-8。

4。Restrepo JF，delRincónI，Battafarano DF，et al。类风湿性关节炎中与间质性肺病相关的临床和实验室因素。Clin Rheumatol。2015; 34：1529至1536年。

5。Tanaka N，Kim JS，Newell JD，et al。类风湿性关节炎相关肺部疾病：CT表现。放射学。2004; 232：81-91。

6。Assayag D，Elicker BM，Urbania TH，et al。类风湿性关节炎相关的间质性肺病：常见间质性肺炎模式的放射学鉴定。放射学。2014; 270：583-8。

7。Assayag D，Lee JS，King TE Jr.类风湿性关节炎相关性间质性肺病：综述。Medicina（B Aires）。2014; 74：158-65。

8。Kim EJ，Elicker BM，Maldonado F，et al。类风湿性关节炎相关的间质性肺病常见的间质性肺炎。Eur Respir J. 2010; 35：1322-8。

9。Pérez-DórameR，MejíaM，Mateos-Toledo H，Rojas-Serrano J.类风湿性关节炎相关性间质性肺病：用高分辨率计算机断层扫描评估的肺部炎症与类风湿性关节炎疾病活动相关。Reumatol Clin。2015; 11：12-6。

10。Perez-Alvarez R，Perez-de-Lis M，Diaz-Lagares C，et al。TNF靶向治疗引起或加剧间质性肺病：122例分析。Semin Arthritis Rheum。2011; 41：256-64。

11。Koo BS，Hong S，Kim YJ，Kim YG，Lee CK，Yoo B，et al。用抗肿瘤坏死因子试剂治疗的类风湿性关节炎相关性间质性肺病患者的死亡率。韩国J实习医生。2015; 30：104-9。

12. Wolfe F, Caplan L, Michaud K. Rheumatoid arthritis treatment and the risk of severe interstitial lung disease. Scand J Rheumatol. 2007;36:172-8.

13. Dixon WG, Hyrich KL, Watson KD, et al. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: Results from the British society for rheumatology biologics register. Ann Rheum Dis. 2010; 69:1086-91.

14. Paulin F, Doyle TJ, Fletcher EA, Ascherman DP, Rosas IO. Rheumatoid arthritis-associated interstitial lung disease and idiopathic pulmonary fibrosis: Shared mechanistic and phenotypic traits suggest overlapping disease mechanisms. Rev Invest Clin. 2015;67:280-6.

15. Aletaha D, Neogi T, Silman AJ, et al 2010 rheumatoid arthritis classification criteria: An American college of rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569-81.

16. Wells G, Becker JC, Teng J, et al. Validation of the 28-joint disease activity score (DAS28) and European league against rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis. 2009;68:954-60.

17. Singh JA, Furst DE, Bharat A, et al 2012 update of the 2008 American college of rheumatology recommendations for the use of disease-modifying Antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64:625-39.

18. Miller MR, Crapo R, Hankinson J, et al. General considerations for lung function testing. Eur Respir J. 2005;26:153-61.

19. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788-824.

20. Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: A simple staging system. Am J Respir Crit Care Med. 2008;177:1248-54.

21. von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology [STROBE] statement: Guidelines for reporting observational studies. Gac Sanit. 2008;22:144-50.

22. Zou YQ, Li YS, Ding XN, Ying ZH. The clinical significance of HRCT in evaluation of patients with rheumatoid arthritis-associated interstitial lung disease: A report from China. Rheumatol Int. 2012;32:669-73.

23. Gochuico BR, Avila NA, Chow CK, et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med. 2008;168:159-66.

24. Fischer A, Solomon JJ, du Bois RM, Deane KD, et al. Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective Tissue disease. Respir Med. 2012;106:1040-7.

25. Gizinski AM, Mascolo M, Loucks JL, et al. Rheumatoid arthritis (RA)-specific autoantibodies in patients with interstitial lung disease and absence of clinically apparent articular RA. Clin Rheumatol. 2009;28:611-3.

26. Ye W, Fifield MC, Östör AJ. Refractory rheumatoid arthritis and associated interstitial lung disease: Could abatacept be the answer? J Clin Rheumatol. 2017;23:125-6.

27. Wuyts WA, Cavazza A, Rossi G, et al. Differential diagnosis of usual interstitial pneumonia: When is it truly idiopathic? Eur Respir Rev. 2014;23:308-19.

28. Rangel-Moreno J, Hartson L, Navarro C, et al. Inducible bronchus-associated lymphoid tissue (iBALT) in patients with pulmonary complications of rheumatoid arthritis. J Clin Invest. 2006; 116:3183-94.

29. Tak PP, Bresnihan B. The pathogenesis and prevention of joint damage in rheumatoid arthritis: Advances from synovial biopsy and tissue analysis. Arthritis Rheum. 2000;43:2619-33.

30. Chatzidionisyou A, Catrina AI. The lung in rheumatoid arthritis, cause or consequence? Curr Opin Rheumatol. 2016;28:76-82.

31. Paulin F, Babini A, Mamani M, Mercado J, Caro F. Practical approach to the evaluation and management of rheumatoid arthritis-interstitial lung disease based on its proven and hypothetical mechanisms. Rev Invest Clin. 2017;69:235-42.

32. Rojas-Serrano J, González-Velásquez E, Mejía M, Sánchez-Rodríguez A, Carrillo G. Interstitial lung disease related to rheumatoid arthritis: Evolution after treatment. Reumatol Clin. 2012;8:68-71.

33。Kazerooni EA，Martinez FJ，Flint A，et al。对于特发性肺纤维化，以10mm增量获得的薄切片CT与有限的三层薄切片CT：与病理评分的相关性。AJR Am J Roentgenol。1997; 169：977-83。